AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00437385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCAs, SSRIs, NARIs, SNRIs, Lithium
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
Study NCT00437385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
Study NCT00437385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy
Description: The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up.
Study NCT00153647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-assisted colonoscopy
Description: Cap-assisted colonoscopy
Study NCT00153647 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cap-assisted colonoscopy
Description: Cap-assisted colonoscopy
Study NCT00621231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00621231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: 30 E% from protein
Study NCT01262937 — intervention group
Intervention type: DEVICE
Intervention: Confocal Imaging
Description: Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
Study NCT04474457 — intervention group
Intervention type: DRUG
Intervention: Favipiravir
Description: Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir.
Study NCT03540082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tuck and Roll Group
Description: An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
Study NCT03540082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fall Exposure
Description: An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
Study NCT02934997 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT00216203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
Study NCT00216203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle
Study NCT03001973 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
Study NCT00005036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00005036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00005036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00005036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00005036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02661698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oil: DHA enriched
Description: 3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
Study NCT02661698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 g capsules Placebo: olive oil
Study NCT02661698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oil: EPA enriched
Description: 3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
Study NCT03660709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5.
Study NCT03660709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard-of-care HIV testing and counseling
Study NCT04066660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligo Fucoidan
Description: 4.4 g oligo fucoidan powder, oral, BID
Study NCT04066660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4.4 g placebo powder, oral, BID
Study NCT01619111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemo- or endocrine therapy
Description: standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)
Study NCT01619111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemo- or endocrine therapy + Lapatinib
Description: Lapatinib~+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)
Study NCT01855698 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT04353596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor, angiotensin receptor blocker
Description: In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
Study NCT00943774 — intervention group
Intervention type: OTHER
Intervention: Physiological maneuvers
Description: These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
Study NCT00703001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: students in this arm will receive several oral health educational modules in class
Study NCT00703001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral Intervention
Description: Parents of enrolled children will receive assistance in accessing oral health care for their child
Study NCT02912299 — intervention group
Intervention type: PROCEDURE
Intervention: Skin biopsies
Description: 2 3mm skin biopsies will be taken
Study NCT02912299 — intervention group
Intervention type: OTHER
Intervention: Blood and urine analysis
Description: Measurement of sodium, potassium and kidneyfunction in blood and urine.
Study NCT02912299 — intervention group
Intervention type: OTHER
Intervention: Blood collection for RNA-investigation
Description: A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
Study NCT01437657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching RO4917523 placebo orally daily, 6 weeks
Study NCT01437657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 0.5 mg
Description: 0.5 mg orally daily, 6 weeks
Study NCT01437657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 1.5 mg
Description: 1.5 mg orally daily, 6 weeks
Study NCT04343742 — intervention group
Intervention type: DRUG
Intervention: chlorine dioxide 3000 ppm
Description: Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
Study NCT01829958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT01829958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00125762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan
Study NCT04092517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Corn Soya Diet
Description: Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
Study NCT04092517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Corn Moringa Diet
Description: Ingredients (% by weight): Maize (78.30); Moringa (20.0)
Study NCT03686956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
Study NCT02442726 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
Description: Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
Study NCT02442726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
Description: Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
Study NCT03480412 — intervention group
Intervention type: PROCEDURE
Intervention: Follicular Phase
Description: The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
Study NCT03480412 — intervention group
Intervention type: PROCEDURE
Intervention: Luteal Phase
Description: Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
Study NCT02334124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home
Description: The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
Study NCT02334124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ward
Description: Admission to a hospital based ward
Study NCT02334124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 50mg/kg once daily
Study NCT02334124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flucloxacillin
Description: 50mg/kg 6 hourly
Study NCT02905253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-084
Description: Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
Study NCT02905253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching AC-084 capsules
Study NCT02294084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
Study NCT02294084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each subject will receive a placebo (once a day) for 12 weeks.
Study NCT00648804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Orally Disintegrating Tablets 8 mg
Description: 8mg, single dose fed
Study NCT00648804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran ODT® Tablets 8 mg
Description: 8mg, single dose fed
Study NCT01313715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
Study NCT01313715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
Study NCT01313715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
Study NCT01313715 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, one month interval
Study NCT03447938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICS CABG
Description: Coronary artery bypass grafting performed through small incisions between the ribs.
Study NCT03447938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
Study NCT00328744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: 18-month standard behavioral weight loss intervention
Study NCT00328744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Limited Variety
Description: Two chosen snack foods
Study NCT03899363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: custom thermoplastic orthosis
Description: extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
Study NCT03899363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom thermoplastic orthosis
Description: extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
Study NCT00646594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Study NCT00646594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol (Advair)
Study NCT00731055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
Study NCT00731055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo
Study NCT05107804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise+CR
Description: Exercise with caloric-restriction
Study NCT05107804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Conditioning
Description: Light Conditioning Exercise
Study NCT01829958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment
Study NCT03228823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
Study NCT03228823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone (Antiarrhythmic drug)
Description: AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
Study NCT00910195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment with subsequent Bi-Level-APAP treatment
Description: CPAP treatment during the first night and then Bi-level-APAP treatment during second night
Study NCT00910195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Level-APAP treatment with subsequent CPAP treatment
Description: Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
Study NCT04236063 — intervention group
Intervention type: OTHER
Intervention: WHODAS 2.0 Questionnaire
Description: 36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
Study NCT01892306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP CBT
Description: The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
Study NCT01892306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Existing optimized pharmacotherapy as delivered by treating psychiatrist
Study NCT01363388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID for 84 days
Study NCT04941677 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study NCT00389038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Skills Training
Description: Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
Study NCT00389038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache Education
Description: Behavioral Treatment 2 (headache education)
Study NCT00389038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
Study NCT03256461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactate clearance 10% target group
Description: Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
Study NCT03256461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactate clearance 20% target group
Description: Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
Study NCT03256461 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard EGDT group
Description: Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
Study NCT00981110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUAGEL Ag Hydrofiber Wound Dressing
Description: Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
Study NCT01363388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: BID for 84 days